Dr Lal PathLabs Q2 Results: Volume Growth Hits 30.6%, FY27 Guidance Upgraded | Business News
ET Now · 05 Nov 2026 · 8 min
Management interview of Dr. Lal PathLabs Ltd (LALPATHLAB), with 5 key numbers discussed.
- Ved Goel, Group CFO and CEO IB, Dr Lal PathLabs
Dr Lal PathLabs has raised its FY27 growth guidance from mid-teens to higher teens on the back of broad-based double-digit volume growth. The company reported 13.6% sample volume growth in Q2FY27 and expects double-digit growth to sustain. It has not implemented price hikes for four years and has no plans for price hikes in H2FY27. Rather than maximising short-term EBITDA margins above 30%, management is reinvesting profits into opening 15-18 new labs, over 800 collection centres, R&D, genomics, radiology, and D2C initiatives.